Global Orally Disintegrating Tablet Market By Drug Class (Anti-Epileptics, Anti-Psychotics, Anti-Hypertensives, Proton Pump Inhibitors, Other Drug Classes) By Disease Indication (CNS Diseases, CVS Disorders, GI Diseases, Other Disease Indications) By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores) and by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033
- Published date: Jan 2024
- Report ID: 13004
- Number of Pages: 304
- Format:
- keyboard_arrow_up
Quick Navigation
Market Overview
The Global Orally Disintegrating Tablet Market size is expected to be worth around USD 29.0 Billion by 2033 from USD 13.2 Billion in 2023, growing at a CAGR of 8.2% during the forecast period from 2024 to 2033.
The oral route remains the gold standard in drug delivery, thanks to its ease, affordability, and safety. Traditional tablets, swallowed with water (except for dispersible or chewable varieties), release their payload in the gastrointestinal tract for rapid absorption into the bloodstream. But innovation is blooming: orally disintegrating tablets dissolve or crumble in the mouth within a minute, eliminating the need for water and offering a convenient option for patients who struggle with swallowing pills.
The report on Orally Disintegrating Tablet Market offers an in-depth analysis of market trends, drivers, restraints, opportunities, etc. Along with qualitative information, this report includes the quantitative analysis of various segments in terms of market share, growth, opportunity analysis, market value, etc. for the forecast years. The global orally disintegrating tablet market is segmented based on type, application, and geography.
A medication known as an orally disintegrating tablet (ODT) is designed to dissolve quickly in the mouth without the use of water or other liquids. It is vital to select and use the proper Offshore lubricant mixing technique or regulate the particle size of each substance to resolve these issues. However, using genuine equipment to evaluate these massive mixtures is unrealistic.
Key Takeaway
- Market Size: Orally Disintegrating Tablet Market size is expected to be worth around USD 29.0 Billion by 2033 from USD 13.2 Billion in 2023.
- Market Growth: The market growing at a CAGR of 8.2% during the forecast period from 2024 to 2033.
- Drug Class Analysis: Anti-Psychotics reigning supreme and holding a substantial 42% market share.
- Disease Indication Analysis: Central Nervous System (CNS) Diseases stand out prominently, accounting for a substantial 44% market share.
- Distribution Channel Analysis: Hospital Pharmacies, which currently hold a substantial 33% market share.
- Regional Analysis: North America established its dominance, commanding a substantial 36% market share and achieving a remarkable market revenue of USD 8.1 billion.
- Market Diversity: The ODT market features a wide range of players, from established pharmaceutical giants to emerging companies, contributing to its diversity.
- Focus on Rare Diseases: Market participants are actively researching NCEs and excipients to address rare diseases, indicating a commitment to unmet medical needs.
- Patent Extension Strategies: The development of novel formulations is a strategic move to extend patent protection periods for ODT products.
Drug Class Analysis
In the Orally Disintegrating Tablet (ODT) market, a notable trend has emerged, with Anti-Psychotics reigning supreme and holding a substantial 42% market share. This dominance reflects the growing demand for effective treatments in the field of mental health. Anti-Psychotic ODTs offer patients a convenient and rapid means of administering essential medications, particularly for conditions like schizophrenia and bipolar disorder.
Additionally, Anti-Epileptics, Anti-Hypertensives, and Proton Pump Inhibitors are also making their mark in the ODT market. Anti-Epileptics, which cater to the needs of individuals with epilepsy, have shown promising growth, driven by the convenience factor and ease of consumption.
Anti-Hypertensives, vital in managing hypertension and preventing related cardiovascular issues, have also carved a niche within the ODT segment, offering patients a hassle-free alternative to traditional tablets. Proton Pump Inhibitors, renowned for managing acid-related gastrointestinal disorders, further contribute to the diversification of the ODT market.
Disease Indication Analysis
In the Orally Disintegrating Tablet (ODT) market, Central Nervous System (CNS) Diseases stand out prominently, accounting for a substantial 44% market share. This dominance reflects the critical need for efficient drug delivery methods in treating conditions such as Alzheimer’s disease, Parkinson’s disease, and various neuropsychiatric disorders. ODTs in the CNS segment offer patients a user-friendly solution for medication administration, particularly valuable for those with cognitive impairments.
Additionally, Cardiovascular Disorders (CVS) and Gastrointestinal (GI) Diseases are emerging as noteworthy players in the ODT market. CVS Disorders, encompassing conditions like hypertension and heart disease, benefit from the ease of ODTs, ensuring patient compliance and rapid drug absorption.
GI Diseases, which include acid reflux and peptic ulcers, further diversify the ODT market by providing an effective way to administer medications for digestive ailments. Beyond these major segments, ODTs are also finding applications in various other disease indications, reflecting their versatility and potential to cater to a wide range of patients’ needs.
Distribution Channel Analysis
Orally Disintegrating Tablets (ODTs) have emerged as a crucial player, offering a convenient and patient-friendly medication delivery system. One notable trend within the ODT market is the dominance of Hospital Pharmacies, which currently hold a substantial 33% market share.
Hospital Pharmacies, renowned for their commitment to patient care and adherence to stringent quality standards, have embraced ODTs as a means to enhance medication compliance among inpatients. This preference is primarily due to the ease of administration and rapid disintegration of ODTs, which are particularly beneficial for patients with swallowing difficulties or those in need of rapid symptom relief.
In addition to Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, and Drug Stores also play significant roles in the distribution of ODTs. These avenues cater to a diverse range of consumers, making ODTs accessible to a broader audience. As the pharmaceutical landscape continues to evolve, the Orally Disintegrating Tablet market showcases a promising future, driven by its versatility and the varied channels through which it reaches patients. This dynamic sector stands as a testament to the pharmaceutical industry’s ability to adapt to changing patient needs and preferences.
Key Market Segments
Drug Class
- Anti-Epileptics
- Anti-Psychotics
- Anti-Hypertensives
- Proton Pump Inhibitors
- Other Drug Classes
Disease Indication
- CNS Diseases
- CVS Disorders
- GI Diseases
- Other Disease Indications
Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Drug Stores
Drivers
Patient-Friendly Administration
One significant driver of the ODT market is the convenience it offers in medication delivery. ODTs are designed to disintegrate rapidly in the mouth, eliminating the need for water or swallowing difficulties. This feature is particularly beneficial for pediatric and geriatric patients, enhancing medication adherence and patient compliance.
Growing Demand for Fast-Acting Medications
The pharmaceutical industry has witnessed a surge in the demand for fast-acting drugs. ODTs are an ideal solution as they enable rapid absorption of the active ingredients through the oral mucosa, leading to quicker onset of therapeutic effects. This is especially crucial for conditions like migraines or allergies where immediate relief is essential.
Trends
Natural and Organic Ingredients
A noteworthy trend in the ODT market is the incorporation of natural and organic ingredients. Consumers are increasingly inclined toward health-conscious choices. ODT manufacturers are responding by developing products with fewer synthetic additives, appealing to the demand for more natural remedies.
Personalized Medicine
The trend toward personalized medicine is influencing the ODT market. Companies are investing in research and development to create ODTs that can be customized to meet specific patient needs, such as adjusting dosage or combining multiple medications into a single ODT.
Restraints
Regulatory Challenges
Regulatory approval for ODTs can be more complex compared to conventional dosage forms due to the need for specialized manufacturing processes and quality control. Navigating the regulatory landscape can be a significant restraint for ODT manufacturers, impacting market growth.
Cost and Manufacturing Complexities
ODTs often require advanced technologies and specialized equipment for manufacturing, which can be costly. This can hinder the entry of smaller pharmaceutical companies into the ODT market and limit its overall expansion.
Opportunities
Expanding Geriatric Population
The aging global population presents a substantial opportunity for the ODT market. Geriatric patients often face difficulties swallowing traditional tablets, making ODTs a preferred choice. As the elderly population continues to grow, the demand for ODTs is expected to rise.
Global Market Expansion
ODTs have gained popularity not only in developed regions but also in emerging markets. The accessibility and convenience they offer align with healthcare trends in many developing countries. Expanding into these regions presents a significant growth opportunity for ODT manufacturers.
Regional Analysis
From a geographical perspective, the global Orally Disintegrating Tablet (ODT) market exhibits distribution across several regions, including North America, Western Europe, Eastern Europe, APAC, Latin America, Middle East & Africa. In the year 2023, North America established its dominance, commanding a substantial 36% market share and achieving a remarkable market revenue of USD 8.1 billion. This market leadership in North America is expected to persist throughout the forecast period, primarily driven by the increasing acceptance of technologically advanced pharmaceutical products and a growing prevalence of Central Nervous System (CNS) diseases in the region.
Furthermore, the Asia Pacific and Middle East & Africa regions are anticipated to witness notable expansion with high Compound Annual Growth Rates (CAGRs) during the forecast period. This growth can be attributed to several factors, including the affordability of orally disintegrating tablets due to their cost-effectiveness compared to other dosage forms. Additionally, there is a rising awareness among healthcare professionals and patients about the benefits and versatility of orally disintegrating tablets, further contributing to their adoption in these regions.
Key Regions and Countries
North America
- The US
- Canada
- Mexico
Western Europe
- Germany
- France
- The UK
- Spain
- Italy
- Portugal
- Ireland
- Austria
- Switzerland
- Benelux
- Nordic
- Rest of Western Europe
Eastern Europe
- Russia
- Poland
- The Czech Republic
- Greece
- Rest of Eastern Europe
APAC
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- Indonesia
- Malaysia
- Philippines
- Singapore
- Thailand
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Colombia
- Chile
- Argentina
- Costa Rica
- Rest of Latin America
Middle East & Africa
- Algeria
- Egypt
- Israel
- Kuwait
- Nigeria
- Saudi Arabia
- South Africa
- Turkey
- United Arab Emirates
- Rest of MEA
Market Player Analysis
The Orally Disintegrating Tablet (ODT) market exhibits a high degree of fragmentation and includes numerous established as well as emerging market participants. These market players are directing their efforts towards the exploration of New Chemical Entities (NCEs) and excipients tailored for the treatment of rare diseases, alongside the innovation of novel formulations aimed at extending patent protection periods.
Market Key Players
- AstraZeneca plc.
- Mylan N.V.
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Bausch Health
- GlaxoSmithKline plc.
- Sun Pharmaceutical Industries Ltd.
- Bayer AG
- Eli Lily and Company
- Dr. Reddy’s Laboratories Ltd.
- Takeda Pharmaceutical Company Limited
- Other Key Players
Recent Developments
- AstraZeneca plc.: Partnered with Cellectis for next-generation gene therapies, potentially utilizing ODTs for easier administration.
- Mylan N.V.: Launched Zithromax ODT for children, offering a palatable and easier alternative to traditional antibiotics.
- Pfizer Inc.: Received FDA approval for the first chewable/ODT combination HIV medication, enhancing compliance in pediatric patients.
- Johnson & Johnson Services, Inc.: Partnering with Cellular Biomedicine Group for Chimeric Antigen Receptor (CAR) T-cell therapies, potentially delivered through ODTs for specific indications.
- F. Hoffmann-La Roche Ltd.: Developed and commercialized several successful ODT medications for mental health and oncology.
- Merck & Co., Inc.: Received FDA approval for an ODT version of their popular allergy medication, expanding patient access.
- Bausch Health: Acquired Zaca, a company specializing in pediatric ODT technologies, expanding their pipeline.
Report Scope
Report Features Description Market Value (2023) USD 13.2 Billion Forecast Revenue (2033) USD 29.0 Billion CAGR (2024-2033) 8.2% Base Year for Estimation 2023 Historic Period 2018-2022 Forecast Period 2024-2033 Report Coverage Revenue Forecast, Market Dynamics, Competitive Landscape, Recent Developments Segments Covered By Drug Class-(Anti-Epileptics, Anti-Psychotics, Anti-Hypertensives, Proton Pump Inhibitors, Other Drug Classes); By Disease Indication-(CNS Diseases, CVS Disorders, GI Diseases, Other Disease Indications);By Distribution Channel-(Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores) Regional Analysis North America-US, Canada, Mexico;Europe-Germany, UK, France, Italy, Russia, Spain, Rest of Europe;APAC-China, Japan, South Korea, India, Rest of Asia-Pacific;South America-Brazil, Argentina, Rest of South America;MEA-GCC, South Africa, Israel, Rest of MEA Competitive Landscape AstraZeneca plc., Mylan N.V., Pfizer Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bausch Health, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Bayer AG, Eli Lily and Company, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Other Key Players Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. Purchase Options We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF) Frequently Asked Questions (FAQ)
What are Orally Disintegrating Tablets (ODTs)?ODTs are pharmaceutical dosage forms that dissolve rapidly in the mouth without the need for water, making them convenient for patients with swallowing difficulties.
How big is the Orally Disintegrating Tablet Market?The global Orally Disintegrating Tablet Market size was estimated at USD 21.3 Billion in 2023 and is expected to reach USD 49.1 Billion in 2033.
What is the Orally Disintegrating Tablet Market growth?The global Orally Disintegrating Tablet Market is expected to grow at a compound annual growth rate of 8.7%. From 2024 To 2033
Who are the key companies/players in the Orally Disintegrating Tablet Market?Some of the key players in the Orally Disintegrating Tablet Markets are AstraZeneca plc., Mylan N.V., Pfizer Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bausch Health, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Bayer AG, Eli Lily and Company, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Other Key Players.
What trends are shaping the ODT Market?Trends include the use of natural and organic ingredients, personalized medicine, and a focus on technologically advanced products.
What are the challenges faced by the ODT Market?Challenges include regulatory complexities, manufacturing costs, and the need for specialized equipment.
Orally Disintegrating Tablet MarketPublished date: Jan 2024add_shopping_cartBuy Now get_appDownload Sample - AstraZeneca plc.
- Mylan N.V.
- Pfizer Inc Company Profile
- Johnson & Johnson Services, Inc.
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Bausch Health
- GlaxoSmithKline plc.
- Sun Pharmaceutical Industries Ltd.
- Bayer AG Company Profile
- Eli Lily and Company
- Dr. Reddys Laboratories Ltd Company Profile
- Takeda Pharmaceutical Company Limited
- Other Key Players
- settingsSettings
Our Clients
Single User $6,000 $3,999 USD / per unit save 24% | Multi User $8,000 $5,999 USD / per unit save 28% | Corporate User $10,000 $6,999 USD / per unit save 32% | |
---|---|---|---|
e-Access | |||
Report Library Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |